JP2023552490A5 - - Google Patents

Info

Publication number
JP2023552490A5
JP2023552490A5 JP2023548533A JP2023548533A JP2023552490A5 JP 2023552490 A5 JP2023552490 A5 JP 2023552490A5 JP 2023548533 A JP2023548533 A JP 2023548533A JP 2023548533 A JP2023548533 A JP 2023548533A JP 2023552490 A5 JP2023552490 A5 JP 2023552490A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
optionally substituted
cycloalkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/055165 external-priority patent/WO2022093552A2/en
Publication of JP2023552490A publication Critical patent/JP2023552490A/ja
Publication of JP2023552490A5 publication Critical patent/JP2023552490A5/ja
Pending legal-status Critical Current

Links

JP2023548533A 2020-10-16 2021-10-15 Rev-erbアゴニスト Pending JP2023552490A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063092893P 2020-10-16 2020-10-16
US63/092,893 2020-10-16
PCT/US2021/055165 WO2022093552A2 (en) 2020-10-16 2021-10-15 Rev-erb agonists

Publications (2)

Publication Number Publication Date
JP2023552490A JP2023552490A (ja) 2023-12-15
JP2023552490A5 true JP2023552490A5 (cg-RX-API-DMAC7.html) 2024-10-21

Family

ID=81384462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548533A Pending JP2023552490A (ja) 2020-10-16 2021-10-15 Rev-erbアゴニスト

Country Status (7)

Country Link
US (1) US20240002380A1 (cg-RX-API-DMAC7.html)
EP (1) EP4228632A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023552490A (cg-RX-API-DMAC7.html)
CN (1) CN116635029A (cg-RX-API-DMAC7.html)
AU (1) AU2021372389A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195127A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022093552A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432302B (zh) * 2020-11-05 2024-08-27 中国科学院上海营养与健康研究所 小分子sr9009在抗衰老以及减轻衰老引起的慢性炎症中的用途
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途
WO2025024550A1 (en) * 2023-07-25 2025-01-30 University Of Florida Research Foundation, Incorporated Rev-erb antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472193A (en) * 1982-07-06 1984-09-18 The Dow Chemical Company Naphthyridinyloxy(or thio)phenoxy propanoic acids, derivatives thereof and methods of herbicidal use
ES2200617B1 (es) * 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
JP5268927B2 (ja) * 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Hcvns3プロテアーゼ阻害剤
WO2008144268A1 (en) * 2007-05-15 2008-11-27 Boehringer Ingelheim International Gmbh Urotensin ii receptor antagonists
UY31984A (es) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
US9593108B2 (en) * 2009-04-06 2017-03-14 Ptc Therapeutics, Inc. Compounds and methods for antiviral treatment
US8952037B2 (en) * 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
WO2013033310A1 (en) * 2011-08-31 2013-03-07 Theodore Mark Kamenecka Modulators of rev-erb
EP2760866B1 (en) * 2011-09-27 2017-12-13 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
MX352181B (es) * 2012-02-02 2017-11-13 Idorsia Pharmaceuticals Ltd Compuestos 4- (benzoimidazol-2-il) -tiazol y derivados aza relacionados.
TW201348231A (zh) * 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
CA2881279C (en) * 2012-08-07 2020-07-07 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
US9908887B2 (en) * 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2015103527A1 (en) * 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
CA2972014C (en) * 2014-12-24 2019-09-24 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of hiv
EP3475275B1 (en) * 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
CN109776335B (zh) * 2017-11-15 2022-03-18 武汉尚赛光电科技有限公司 芘的胺类衍生物及其制备方法、应用和器件
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells

Similar Documents

Publication Publication Date Title
TWI765451B (zh) 作為erk抑制劑的螺環類化合物及其應用
JP2007501862A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2023535598A5 (cg-RX-API-DMAC7.html)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2021521200A5 (cg-RX-API-DMAC7.html)
JP2021523225A5 (cg-RX-API-DMAC7.html)
JP2025524914A5 (cg-RX-API-DMAC7.html)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2024001048A5 (cg-RX-API-DMAC7.html)
RU2014138827A (ru) Антагонисты рецептора андрогена и их применение
JP2020533352A5 (cg-RX-API-DMAC7.html)
JP7019000B2 (ja) 2環性複素環化合物
RU2010126063A (ru) Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора
CN110662752B (zh) 用于临床管理由衰老细胞引起或介导的病症以及治疗癌症的Bcl家族拮抗剂磷杂环化合物
JP2023520396A5 (cg-RX-API-DMAC7.html)
JP2021530513A5 (cg-RX-API-DMAC7.html)
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
JP2022533939A5 (cg-RX-API-DMAC7.html)
JP2023553428A5 (cg-RX-API-DMAC7.html)
JP2023544716A5 (cg-RX-API-DMAC7.html)
JP2000506150A (ja) 新規なアリールグリシンアミド誘導体、その製造方法及び該誘導体を含む医薬組成物
JP2023538524A5 (cg-RX-API-DMAC7.html)
JP2022539126A (ja) ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用
JP2024522718A5 (cg-RX-API-DMAC7.html)